𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in congenital coagulation disorders. A randomised, double-blind, placebo-controlled clinical trial

✍ Scribed by K. Meijer; M.C. Kappers-Klunne; I.R.O. Novakova; E.P. Mausser-Bunschoten; M.M.W. Koopman; P.J. Voogt; F.W.G. Leebeek; E.B. HaagsmA; W.M. Smid; J. Schirm; N.J.G.M. Veeger; J. Van der Meer

Book ID
117372681
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
320 KB
Volume
38
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-daily induction dose of interferon
High-daily induction dose of interferon in combination with ribavirin in chronic hepatitis C non responder patients: a randomised controlled trial: Vincent Leroy Mr, Nadine Dutertre, CHU Grenoble, Grenoble France; Albert Tran, CHU Nice, Nice France; Sylvie Naveau, CHU Clamart, Clamart France; Armand Abergel, CHU Clermond-Ferrand, Clermond-Ferrand France; Marc Bourliere, Hopital Saint-Joseph, Marseille France; Agnes Plages, Jean-Pierre Zarski, CHU Grenoble, Grenoble France
📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB
A phase II randomized, double-blind, pla
A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA
📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB
Randomized, double-blind, placebo-contro
Randomized, double-blind, placebo-controlled trial of high-dose interferon-alfa induction combination therapy with and without amantadine sulphate in previously untreated patients the chronic hepatitis C: Thomas Berg, Charité, Campus Virchow-Klinikum, Humboldt-Univ, Berlin Germany; Bernd Kronenberger, Medizinische Universitätsklinik, Frankfurt Germany; Holger Hinrichsen, Medizinische Universitätsklinik, Kiel Germany; Tilman Gerlach, Midizinische Universitätsklinik Groβhadern, München Germany; Peter Buggisch, Medizinische Universitätsklinik Eppendorf, Hamburg Germany; Ulrich Spengler, Medizinische Universitätsklinik, Bonn Germany; Tobias Goeser, Medizinische Universitätsklinik, Köln Germany; Renate Baumgarten, Krankenhaus Prenzlauer Berg, Berlin Germany; Gerd R Pape, Medizinische Universitätsklinik Groβhadern, München Germany; Uwe Hopf, Charité Campus Virchow-Klinikum, Humboldt-Univ, Berlin Germany; Stefan Zeuzem, Medizinische Universitätsklinik, Frankfurt Germany
📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB